Stereoselective Synthesis of (+)-Saxitoxin
A R T I C L E S
with specific channel isoforms. Because of the general absence
of detailed structural information on most ion channel
proteins, however, the de noVo design of such chemical
agents is exceedingly difficult.8 Fortunately, Nature has provided
a number of topologically unique, low molecular weight
compounds that act as modulators of ion channel proteins;
such compounds can serve as scaffolds from which to
craft new materials with unprecedented pharmacological
properties.
The paralytic shellfish poison, (+)-saxitoxin, most notably
associated with outbreaks of red tide, was first isolated in pure
form by Schantz in 1957 and structurally characterized by X-ray
analysis by the groups of Schantz/Clardy and Rapoport in
1975.9,10 This small molecule is among the most lethal non-
proteinaceous substances known, its acute toxicity resulting from
its ability to disable ionic conductance through the voltage-gated
sodium channel, a characteristic shared by the fugu poison, (-)-
tetrodotoxin (TTX).11,12 At a molecular level, STX and TTX
act by occluding the channel pore, lodging with nanomolar
affinity in the extracellular mouth of certain voltage-gated Na+
channel isoforms.11,13 Physiological studies of the Na+ channel
protein have been empowered with the availability of STX,
TTX, and a small number of naturally occurring isolates having
related guanidinium structures.14 More information pertinent to
understanding both Na+ channel structure and function would
be gained if specific chemical tailoring could be done to either
toxin.15 Semisynthetic protocols, however, have proven largely
ineffective for modifying these heteroatom-rich, charged, hy-
drophilic natural products.11a,16 The development of a concise,
easily modified route to STX is therefore warranted, as it is
only through total synthesis that the potential of STX to serve
as a blueprint for new Na+ channel blockers having designed
function may be realized.
Figure 2. Retrosynthetic scheme for STX assembly: two strategies for
accessing the nine-membered ring guanidine 2.
Results and Discussion
Synthetic Plan. The challenges associated with STX as a
target for chemical synthesis arise, in part, from the remarkably
dense configuration of heteroatoms about its tricyclic core. As
indicated by the molecular formula, C10H19N7O4, the total carbon
count is in fact less than the combined number of oxygen and
nitrogen atoms that comprise the natural product. Furthermore,
the dicationic nature of STX adds complications to the handling
and purification of this target. Nevertheless, shortly after the
molecular structure of STX was revealed by X-ray analysis,
two highly creative synthetic plans for its preparation were
described.4,5 In both instances the tricyclic core of the natural
product is first assembled and the desired toxin is revealed
following a common end-game strategy where pseudourea
moieties are converted to their guanidinium equivalents. Ac-
cordingly, a more expeditious synthesis of STX might avoid
these types of late-stage functional group exchange reactions
and put directly in place the intact guanidinium groups.
Following this line of analysis, unraveling the tetrasubstituted
C4 aminal to its component parts, a C4 ketone and two
guanidine units, thus became a defining disconnection in our
approach (Figure 2). Such a plan posits that all three rings of
the STX core can be formed from a nine-membered ring bis-
guanidine 1. Importantly, the stereochemical configuration of
the tetrasubstituted C4 aminal position would be controlled by
the chirality of the attendant groups at C5 and C6. Although
the decision to prepare a medium-sized ring intermediate such
as 1 would not appear simplifying at first glance, such a move
transforms a highly complex problem in stereocontrolled cyclic
synthesis to the seemingly more manageable problem of
preparing an acyclic polyamine (e.g., 3 or 4) en route to 1. The
assembly of such an acyclic material could capitalize on the
utility of our directed C-H amination methods.
(8) Potassium and chloride ion channels have been characterized crystallo-
graphically. For recent reviews of this work, see: (a) Tombola, F.; Pathak,
M. M.; Isacoff, E. Y. Annu. ReV. Cell DeV. Biol. 2006, 22, 23-52. (b)
Dutzler, R. Curr. Opin. Struct. Biol. 2006, 16, 439-446. (c) Gouaux, E.;
MacKinnon, R. Science 2005, 310, 1461-1465.
(9) Schantz, E. J.; Mold, J. D.; Stanger, D. W.; Shavel, J.; Riel, F. J.; Bowden,
J. P.; Lynch, J. M.; Wyler, R. S.; Riegel, B.; Sommer, H. J. Am. Chem.
Soc. 1957, 79, 5230-5235.
(10) (a) Schantz, E. J.; Ghazarossian, V. E.; Schnoes, H. K.; Strong, F. M.;
Springer, J. P.; Pezzanite, J. O.; Clardy, J. J. Am. Chem. Soc. 1975, 97,
1238-1239. (b) Bordner, J.; Thiessen, W. E.; Bates, H. A.; Rapoport, H.
J. Am. Chem. Soc. 1975, 97, 6008-6012.
(11) (a) Tetrodotoxin, Saxitoxin, and the Molecular Biology of the Sodium
Channel; Kao, C. Y., Levinson, S. R., Eds.; Annals of the New York
Academy Science: New York, 1986; Vol. 479. (b) Narahashi, T. J. Toxicol.,
Toxin ReV. 2001, 20, 67-84. (c) Novakovic, S. D.; Eglen, R. M.; Hunter,
J. C. Trends Neurosci. 2001, 24, 473-478.
(12) (a) Evans, M. H. Br. J. Pharmacol. Chemother. 1964, 22, 478-479. (b)
Kao, C. Y.; Nishiyama, A. J. Physiol. (London, U.K.) 1965, 1, 50-51. (c)
Kao, C. Y. Pharmacol. ReV. 1966, 2, 997-1049.
(13) For a general discussion of Na+ channel isoforms, see: (a) Catterall, W.
A.; Goldin, A. L.; Waxman, S. G. Pharmacol. ReV. 2003, 55, 575-578.
(b) Catterall, W. A.; Goldin, A. L.; Waxman, S. G. Pharmacol. ReV. 2005,
57, 397-409.
The preparation of medium-sized rings, particularly hetero-
cycles of eight and nine units in size, is challenging, and the
construction of a nine-membered cyclic guanidine is without
precedent.17,18 In considering approaches to compounds such
as 1, two strategies were most appealing: ring closing-metathesis
(14) (a) Hall, S.; Strichartz, G.; Moczydlowski, E.; Ravindran, A.; Reichardt,
P. B. ACS Symp. Ser. 1990, 418, 29-65. (b) Yotsu-Yamashita, M. J.
Toxicol., Toxin ReV. 2001, 20, 51-66. (c) Llewellyn, L. E. Nat. Prod. Rep.
2006, 23, 200-222. (d) Llewellyn, L.; Negri, A.; Robertson, A. J. Toxicol.,
Toxin ReV. 2006, 25, 159-196.
(15) Kishi has prepared a small number of STX derivatives through de novo
synthesis, see: Strichartz, G. R.; Hall, S.; Magnani, B.; Hong, C. Y.; Kishi,
Y.; Debin, J. A. Toxicon 1995, 33, 723-737.
(16) (a) Koehn, F. E.; Ghazarossian, V. E.; Schantz, E. J.; Schnoes, H. K.; Strong,
F. M. Bioorg. Chem. 1981, 10, 412-428. (b) Hu, S. L.; Kao, C. Y.; Koehn,
F. E.; Schnoes, H. K. Toxicon 1987, 25, 159-165. (c) Sato, S.; Sakai, R.;
Kodama, M. Bioorg. Med. Chem. Lett. 2000, 10, 1787-1789. (c) Watanabe,
R.; Samusawa-Saito, R.; Oshima, Y. Bioconjugate Chem. 2006, 17, 459-
465.
(17) For general reviews on the synthesis of medium-sized rings, see: (a) Evans,
P. A.; Holmes, A. B. Tetrahedron 1991, 47, 9131-9166. (b) Yet, L. Chem.
ReV. 2000, 100, 2963-3007.
(18) The assembly of an eight-membered ring guanidine has been reported;
however, the formation of a nine-membered ring was not possible under
the same conditions, see: Fukada, N.; Takano, M.; Nakai, K.; Kuboike,
S.; Takeda, Y. Bull. Chem. Soc. Jpn. 1993, 66, 148-152.
9
J. AM. CHEM. SOC. VOL. 129, NO. 32, 2007 9965